跳至主要内容
临床试验/NCT00465959
NCT00465959已完成1 期

Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Endo Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Safety and efficacy (measured by spirometry) of TrIP will be assessed in patients with chronic obstructive pulmonary disease.

研究概览

简要总结

To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female COPD patients between the ages of 40 and 80 years
  • Smoking history of at least 10 pack years
  • Not currently using (or able to wash out of) any long acting bronchodilators

排除标准

  • Candidate on a waiting list for surgery while on study
  • Using long-term oxygen therapy
  • Hospitalization for COPD exacerbation

研究组 & 干预措施

400 mg TrIP

Experimental

干预措施: trospium chloride inhalation powder (TrIP) (Drug)

800 mg TrIP

Experimental

干预措施: trospium chloride inhalation powder (TrIP) (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Safety and efficacy (measured by spirometry) of TrIP will be assessed in patients with chronic obstructive pulmonary disease.

次要结局

未报告次要终点

研究者

发起方
Endo Pharmaceuticals
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验